SIRT3 and hepatocellular carcinoma: Jin and colleagues proved that SIRT3 suppresses HCC development by delactylating cyclin E2 (CCNE2), a lactylated substrate of SIRT3, thereby reducing its ability to promote tumor growth in HCC cells [69].